Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference
Gain Therapeutics (Nasdaq: GANX) announced that COO Matthias Alder will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Gain Therapeutics (Nasdaq: GANX) announced that COO Matthias Alder will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. The presentation is scheduled for September 12 at 7:00 AM ET and will be available via a webcast. Gain Therapeutics focuses on transforming drug discovery with its proprietary SEE-Tx® platform, targeting allosteric binding sites to develop treatments for various diseases, including neurodegenerative and metabolic disorders.
Details
News Market Reaction – GANX
The recorded move for GANX in the trading session of this news was -3.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14 in New York, NY. Please see additional details below:
H.C. Wainwright 24th Annual Global Investment Conference
Date: September 12, 2022
Time: 7:00AM ET
Format: Corporate Presentation
Webcast: Registration link
A webcast of the presentation can be accessed through the Events section of the Company’s website at https://www.gaintherapeutics.com/investors-media/overview.html. An archived replay of the webcast will be available on the Company’s website following the conference.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.
Investor & Media Contact:
Noor Pahlavi
Argot Partners
(212) 600-1902
Gain@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.